Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Apr-01-23 | Jul-02-22 | Apr-02-22 | Dec-31-21 | Oct-02-21 | Jul-03-21 | Apr-03-21 | Dec-31-20 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues: |
| Academic and government | | 296.2 | 289.9 | 289.6 | 285.4 | 292.2 | 286.7 | 270.6 |
| Net Sales Recognized at a Point in Time | | 2,283.5 | 2,252.0 | 2,176.7 | 2,154.3 | 2,118.5 | 1,982.5 | 1,863.1 |
| Product | | | | | | | | 1,497.3 |
| Pharmaceutical | | 1,743.2 | 1,722.7 | 1,667.1 | 1,635.6 | 1,580.2 | 1,474.6 | 1,387.0 |
| Total revenues | | 2,900.6 | 2,867.9 | 2,785.9 | 2,736.1 | 2,670.6 | 2,509.0 | 2,365.4 |
| Revenue growth [+] | | 8.6% | 14.3% | 17.8% | 19.2% | 17.2% | 6.4% | -1.7% |
| Academic and government | | 1.3% | 1.1% | 7.0% | | | | |
| Net Sales Recognized at a Point in Time | | 7.8% | 13.6% | 16.8% | 20.8% | 20.3% | 7.8% | -1.4% |
| Product | | | | | | | | -4.5% |
| Pharmaceutical | | 10.3% | 16.8% | 20.2% | 24.0% | 21.2% | 9.8% | 1.6% |
| Cost of goods sold | | 1,215.0 | 1,188.1 | 1,156.5 | 1,126.1 | 1,117.3 | 1,050.2 | 1,006.7 |
| Gross profit | | 1,685.6 | 1,679.8 | 1,629.3 | 1,610.0 | 1,553.3 | 1,458.8 | 1,358.7 |
| Gross margin | | 58.1% | 58.6% | 58.5% | 58.8% | 58.2% | 58.1% | 57.4% |
| Selling, general and administrative [+] | | 644.9 | 641.2 | 627.0 | 607.0 | 589.9 | 549.2 | 553.7 |
| Sales and marketing | | 471.9 | 468.2 | | 454.0 | 436.8 | 396.1 | |
| General and administrative | | | | 173.0 | | | | 153.1 |
| Research and development | | 169.8 | 170.7 | 168.4 | 164.7 | 157.7 | 143.9 | 140.8 |
| EBITDA [+] | | 997.9 | 993.9 | 958.6 | 962.4 | 926.6 | 883.5 | 779.0 |
| EBITDA growth | | 7.7% | 12.5% | 23.1% | 30.9% | 24.2% | 15.3% | -4.3% |
| EBITDA margin | | 34.4% | 34.7% | 34.4% | 35.2% | 34.7% | 35.2% | 32.9% |
| Depreciation | | 73.6 | 72.4 | 71.6 | 72.0 | 70.4 | 69.3 | 68.7 |
| EBITA | | 924.3 | 921.4 | 887.0 | 890.3 | 856.3 | 814.1 | 710.3 |
| EBITA margin | | 31.9% | 32.1% | 31.8% | 32.5% | 32.1% | 32.4% | 30.0% |
| Amortization of intangibles | | 60.2 | 60.6 | 60.1 | 60.2 | 59.5 | 58.2 | 56.7 |
| EBIT [+] | | 864.1 | 860.9 | 826.9 | 830.2 | 796.7 | 755.9 | 653.6 |
| EBIT growth | | 8.5% | 13.9% | 26.5% | 34.0% | 25.6% | 15.2% | -7.7% |
| EBIT margin | | 29.8% | 30.0% | 29.7% | 30.3% | 29.8% | 30.1% | 27.6% |
| Non-recurring items [+] | | | 15.0 | 5.2 | | | | 8.1 |
| In-process research & development | | | 9.8 | | | | | |
| Interest expense, net [+] | | 35.4 | 34.8 | 32.7 | 30.5 | 28.9 | 29.6 | 32.8 |
| Interest expense | | 44.4 | 45.1 | 44.9 | 45.1 | 44.9 | 45.9 | 49.1 |
| Interest income | | 9.1 | 10.2 | 12.2 | 14.6 | 16.0 | 16.3 | 16.3 |
| Other income (expense), net [+] | | 0.2 | 8.0 | 17.2 | 18.4 | 18.0 | 8.0 | -1.8 |
| Other | | 0.2 | 8.0 | 17.2 | 18.4 | 18.0 | 8.0 | -1.8 |
| Pre-tax income | | 814.0 | 819.1 | 806.2 | 811.1 | 778.9 | 726.8 | 610.9 |
| Income taxes | | 111.8 | 114.6 | 113.4 | 116.2 | 118.4 | 110.7 | 89.3 |
| Tax rate | | 13.7% | 14.0% | 14.1% | 14.3% | 15.2% | 15.2% | 14.6% |
| Net income | | 702.1 | 704.5 | 692.8 | 694.9 | 660.5 | 616.1 | 521.6 |
| Net margin | | 24.2% | 24.6% | 24.9% | 25.4% | 24.7% | 24.6% | 22.1% |
| |
| Basic EPS [+] | | $11.55 | $11.52 | $11.25 | $11.24 | $10.65 | $9.93 | $8.40 |
| Growth | | 8.4% | 16.1% | 33.9% | 41.5% | 33.3% | 22.5% | -2.6% |
| Diluted EPS [+] | | $11.47 | $11.44 | $11.17 | $11.16 | $10.59 | $9.88 | $8.36 |
| Growth | | 8.4% | 15.8% | 33.6% | 41.3% | 33.4% | 22.8% | -2.3% |
| |
| Shares outstanding (basic) [+] | | 60.8 | 61.2 | 61.6 | 61.8 | 62.0 | 62.1 | 62.1 |
| Growth | | -2.0% | -1.5% | -0.8% | -2.5% | -3.9% | -6.3% | -9.6% |
| Shares outstanding (diluted) [+] | | 61.2 | 61.6 | 62.0 | 62.3 | 62.4 | 62.4 | 62.4 |
| Growth | | -1.9% | -1.2% | -0.6% | -2.4% | -3.9% | -6.6% | -9.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|